Please activate JavaScript!
Please install Adobe Flash Player, click here for download

discovered_01_2015

FOCUS// THE HZDR RESEARCH MAGAZINE WWW.HZDR.DE 20 21 released from the nucleus of the cell. One of them is the ‘La’-protein, which sticks to the surface of the remaining intact tumor cells. Arndt’s and Bachmann’s modular system can exploit this because the effector module can bind the ‘La’-protein, which naturally contains the peptide-epitope. This feature alone allows the effector module to introduce immune cells into areas of the tumor that have already been treated with radiation – without any involvement of the target modules. And if that is not enough to defeat the cancer, radioactive isotopes could be built into one of the target modules. In cooperation with her colleagues from the Institute of Radiopharmaceutical Cancer Research, Arndt wants to improve the modular system by introducing radionuclides and then test whether the target-seeking antibody will only accumulate in the tumor. In this way, radiation would only damage the cancer cells and not the healthy cells in the rest of the body. Arndt has just started this project, which means that she will continue to play with her molecular Legos for some time to come. PUBLICATIONS: C. Arndt et al.: ‘Simultaneous targeting of prostate stem cell antigen and prostate-specific membrane antigen improves the killing of prostate cancer cells using a novel modular T-cell-retargeting system’, in Prostate 2014 (DOI 10.1002/ pros.22850) C. Arndt et al.: ‘Costimulation improves the killing capability of T-cells redirected to tumor cells expressing low levels of CD33: Description of a novel modular targeting system’, in Leukemia 2014 (DOI: 10.1038/leu.2013.242) C. Arndt et al.: ‘Redirection of T-cells with a first fully humanized bispecific CD33-CD3 antibody efficiently eliminates AML blasts without harming hematopoietic stem cells’, in Leukemia 2013 (DOI: 10.1038/leu.2013.18) CONTACT _Institute of Radiopharmaceutical Cancer Research at HZDR Dr. Claudia Arndt c.arndt@hzdr.de MICROPLATE: Claudia Arndt conducts complex experiments to find out how immune cells can dock on cancer cells. Photo: Frank Bierstedt

Seitenübersicht